This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!
Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log in
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Dec 31:4:30087.
doi: 10.3402/jev.v4.30087. eCollection 2015.

Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper

Thomas Lener 1 2 , Mario Gimona 1 2 , Ludwig Aigner 1 , Verena Börger 3 , Edit Buzas 4 , Giovanni Camussi 5 , Nathalie Chaput 6 7 , Devasis Chatterjee 8 9 , Felipe A Court 10 , Hernando A Del Portillo 11 12 , Lorraine O'Driscoll 13 14 , Stefano Fais 15 , Juan M Falcon-Perez 16 17 , Ursula Felderhoff-Mueser 18 , Lorenzo Fraile 19 , Yong Song Gho 20 , André Görgens 3 , Ramesh C Gupta 21 22 , An Hendrix 23 , Dirk M Hermann 24 , Andrew F Hill 25 , Fred Hochberg 26 , Peter A Horn 3 , Dominique de Kleijn 27 , Lambros Kordelas 28 , Boris W Kramer 29 , Eva-Maria Krämer-Albers 30 , Sandra Laner-Plamberger 1 2 , Saara Laitinen 31 , Tommaso Leonardi 32 33 , Magdalena J Lorenowicz 34 , Sai Kiang Lim 35 , Jan Lötvall 36 , Casey A Maguire 37 , Antonio Marcilla 38 39 , Irina Nazarenko 40 , Takahiro Ochiya 41 , Tushar Patel 42 , Shona Pedersen 43 , Gabriella Pocsfalvi 44 , Stefano Pluchino 32 , Peter Quesenberry 8 9 , Ilona G Reischl 45 , Francisco J Rivera 46 , Ralf Sanzenbacher 47 , Katharina Schallmoser 1 2 , Ineke Slaper-Cortenbach 48 , Dirk Strunk 49 , Torsten Tonn 50 , Pieter Vader 51 52 , Bas W M van Balkom 53 , Marca Wauben 54 , Samir El Andaloussi 52 55 , Clotilde Théry 7 56 , Eva Rohde 1 57 , Bernd Giebel 58
Affiliations

Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper

Thomas Lener et al. J Extracell Vesicles. .

Abstract

Extracellular vesicles (EVs), such as exosomes and microvesicles, are released by different cell types and participate in physiological and pathophysiological processes. EVs mediate intercellular communication as cell-derived extracellular signalling organelles that transmit specific information from their cell of origin to their target cells. As a result of these properties, EVs of defined cell types may serve as novel tools for various therapeutic approaches, including (a) anti-tumour therapy, (b) pathogen vaccination, (c) immune-modulatory and regenerative therapies and (d) drug delivery. The translation of EVs into clinical therapies requires the categorization of EV-based therapeutics in compliance with existing regulatory frameworks. As the classification defines subsequent requirements for manufacturing, quality control and clinical investigation, it is of major importance to define whether EVs are considered the active drug components or primarily serve as drug delivery vehicles. For an effective and particularly safe translation of EV-based therapies into clinical practice, a high level of cooperation between researchers, clinicians and competent authorities is essential. In this position statement, basic and clinical scientists, as members of the International Society for Extracellular Vesicles (ISEV) and of the European Cooperation in Science and Technology (COST) program of the European Union, namely European Network on Microvesicles and Exosomes in Health and Disease (ME-HaD), summarize recent developments and the current knowledge of EV-based therapies. Aspects of safety and regulatory requirements that must be considered for pharmaceutical manufacturing and clinical application are highlighted. Production and quality control processes are discussed. Strategies to promote the therapeutic application of EVs in future clinical studies are addressed.

Keywords: haematology; immunology; neurobiology; regulation; stem cells; tissue regeneration; tumour vaccination.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Pharmaceutical categories and a suggested classification of EV-based therapeutics. Chart depicts the Categories of Medicinal Products with respect to their origin (chemical, biological, herbal). Medicinal Products (according to DIRECTIVE 2001/83/EC) include any substance or combination of substances for treating or preventing disease in humans. Any substance or combination of substances which may be administered to humans with a view to making a medical diagnosis or to restoring, correcting or modifying physiological functions in humans is likewise considered a medicinal product. The suggested classification of EV-based therapeutics within the class of biological medicinal products is provided (grey fields). Bold indicates categories from which existing legislation is recommended to be considered for preclinical and clinical development of EV-therapeutics.

References

    1. Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol. 2013;200:373–83. - PMC - PubMed
    1. Yanez-Mo M, Siljander PR, Andreu Z, Zavec AB, Borras FE, Buzas EI, et al. Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles. 2015;4 27066, doi: http://dx.doi.org/10.3402/jev.v4.27066. - DOI - PMC - PubMed
    1. Kim DK, Lee J, Kim SR, Choi DS, Yoon YJ, Kim JH, et al. EVpedia: a community web portal for extracellular vesicles research. Bioinformatics. 2015;31:933–9. - PMC - PubMed
    1. Harding C, Heuser J, Stahl P. Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes. J Cell Biol. 1983;97:329–39. - PMC - PubMed
    1. Pan BT, Johnstone RM. Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor. Cell. 1983;33:967–78. - PubMed
Cite

AltStyle によって変換されたページ (->オリジナル) /